P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3

• Cyrille Touzeau,
• Nizar J Bahlis,
• Christopher Maisel,
• Lionel Karlin,
• Asya Nina Varshavsky-Yanovsky,
• Eric Leip,
• Umberto Conte,
• Andrea Viqueira,
• Sarah M. Larson

Affiliations

Cyrille Touzeau

1 CHU de Nantes, Nantes, France

Nizar J Bahlis

2 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada

Christopher Maisel

3 Baylor University Medical Center, Dallas, United States

Lionel Karlin

4 Centre Hospitalier Lyon Sud - Service d’Hematologie Clinique, Lyon, France

Asya Nina Varshavsky-Yanovsky

5 Fox Chase Cancer Center, Philadelphia, United States

Eric Leip

6 Pfizer Inc, Cambridge, United States

Umberto Conte

7 Pfizer Inc., New York, United States

Andrea Viqueira

8 Pfizer SLU, Madrid, Spain

Sarah M. Larson

9 University of California Los Angeles Medical Center, Los Angeles, United States